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The most important pharmacodynamic parameter for /?-lactam antibiotics has been
shown to be the time above the MIC, which is used as an argument to administer
/?-lactam antibiotics by continuous infusion. Studies in vitro and in laboratory
animals comparing efficacy of continuous and intermittent infusion of /J-lactam
antibiotics generally show continuous infusion to be more efficacious. While
comparative trials in humans are scarce and a significant difference was only found
in subgroup analysis in one study, several case-reports support the use of continuous
infusion. Arguments in favour and against continuous infusion are discussed.
Although dose-ranging studies have not yet been performed in humans, the results
from in-vitro and in-vivo experiments indicate that 4 x MIC for the infecting
bacterium would be the target concentration. Pharmacokinetic studies which have
been performed in humans during continuous infusion show that serum
concentrations can be predicted from total clearance or, using population
pharmacokinetic modelling, the elimination rate constant as obtained during
intermittent infusion. A nomogram is presented which allows calculation of the daily
dose to obtain the target steady state blood concentrations suggested by the
susceptibility of the infecting bacterium, usually 4 x MIC. For bacteria with a low
MIC, the daily dose may be substantially lower than that used in conventional dosing
regimens, while in infections which are difficult to treat as a result of more resistant
bacteria, continuous infusion may be more effective than an equivalent bolus dose.
Introduction
Several pharmacodynamic parameters of antimicrobial agents have been correlated with
efficacy or outcome. The most important such pharmacodynamic parameter for
/Mactam antibiotics has been shown to be the time above MIC (Drusano, 1991; Craig
& Ebert, 1992). This finding is used as an argument to administer /Mactam antibiotics
by continuous infusion. In this article the arguments in favour and against continuous
infusion are discussed with emphasis on clinical relevance of the issues raised.
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Studies in vitro and in laboratory animals
In-vitro studies of the pharmacodynamics of /?-lactam antibiotics have shown that
killing of bacteria, in particular Gram-negative aerobic rods, is slow, time dependent,
and maximal at relatively low concentrations (Vogelman & Craig, 1986).
Concentrations much higher than the MIC provide no extra benefit. These observations
have led to the hypothesis that continuously maintained concentrations above a certain
level, related to the MIC for the bacterium against which therapy is directed, would be
more efficacious than the high peak and trough concentrations obtained with an
intermittent dosing regimen. High peak concentrations have no value, and growth of
bacteria resumes when concentrations decline to below the MIC. This is in constrast
to, for instance, the pharmacodynamic behaviour of the aminoglycosides, where efficacy
is concentration dependent.
Efficacy studies in laboratory animals are in agreement with these in-vitro findings.
Several groups have performed studies comparing intermittent dosing regimens with
continuous infusion. The results of these studies have been summarised by Craig &
Ebert (1992). In one graph, summarising all published data, the daily dose needed to
treat 50% of the animals successfully (the ED50) during continuous infusion was
compared with that needed by intermittent infusion to obtain the same efficacy. If both
treatment regimens yielded equal results, the slope of the equal potency line would be
unity, being a function of the MIC for the relevant bacterium, and the intercept would
be zero. Instead, the line was shifted to the right. Overall, the daily doses needed to
obtain the same efficacy were eight-fold higher during intermittent infusion regimens
than with continuous infusion. In another experimental setting, to demonstrate that
time above the MIC is a most important pharmacodynamic parameter for the efficacy
of /Mactams, Onyeji el al. (1994) used different dosing regimens of ceftabuten and
cefaclor, administering the same total daily dosage as between one and sixteen doses.
The percentage survival of the animals used increased linearly with the frequency of
dosing and the time above the MIC. A similar result was obtained when pneumococci
with varying MICs were used in a mouse peritonitis model (Knudsen, Frimodt-Moller
& Espersen, 1995). In that study, a direct relationship between ED50 could be found
with time above the MIC but not with other pharmacodynamic parameters.
One of the problems in extrapolating these results from animals to humans, is the
different pharmacokinetics in the animals used. In rodents, the half-life of most
/?-lactams is approximately 20 min, which is much shorter than in humans. Even with
an intermittent dosing regimen of four times daily, concentrations in serum decline
rapidly, and fall below efficacious concentrations within 1 to 2 h. If only the time above
the MIC is considered, it would compare with a once daily dose in humans, which with
a few exceptions, is generally considered completely inadequate.
One way to deal with this problem, is to simulate human pharmacokinetics in an
in-vitro model, and to study efficacy during continuous and intermittent infusion.
Results from these studies also showed increased efficacy during continuous infusion
when Pseudomoncis aeruginosa infections were treated with ceftazidime (Mouton & den
Hollander, 1994; Cappelletty el al., 1995). Other approaches which have been used
successfully, are manipulation of the study animals by producing renal dysfunction to
decrease total body clearance (Giacomini, Roberts & Levy, 1981) or administration of
fractionized decreasing doses (Fluckiger, Segessenmann & Gerber, 1991). Results from
these studies are generally in agreement with earlier findings.
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Clinical efficacy studies
To determine whether the time the serum concentration is above the MIC, among other
parameters, is an important pharmacodynamic parameter for /Mactams in humans,
Schentag et al. (1984) studied the efficacy of cefmenoxime in patients with
Gram-negative pneumonia, and correlated the time serum concentrations were above
the MIC with bacterial eradication. They found a significant relationship between time
to eradication of the bacteria and time above the MIC.
Reports on the efficacy of continuous infusion compared to intermittent
administration in humans are still scarce. Only two randomised trials have compared
the efficacy of /Mactams given by these two dosing-regimens, but definite conclusions
from these trials could not be made. In a French study (Lagast, Meunier-Carpentier
& Klasterski, 1983), 45 bacteraemic patients were treated with cefoperazone either by
intermittent administration or by continuous infusion, but no statistically significant
differences in efficacy were found between the two regimens. The power of this study,
however, was quite low. In the study of Bodey, Ketchel & Rodriguez (1979), the efficacy
of continuous versus intermittent infusion of cefamandole, in combination with
carbenicillin, was compared. Although no overall significant difference was found
between the two groups, subgroup analysis showed that the patients with persisting
neutropenia and/or the patients with organisms susceptible to cefamandole did
significantly better when receiving cefamandole as a continuous infusion. This
significant finding in a small number of patients suggest that continuous infusion could
be of substantial benefit. Efficacy of continuous infusion of ceftazidime was studied in
patients with cystic fibrosis. Although these were non-controlled studies, treatment was
efficacious. A few case reports also support the use of continuous infusions of
ceftazidime in cystic fibrosis (Daenen & de Vries-Hospers, 1988; David & Devlin, 1989;
Kuzemko & Crawford, 1989).
Continuous infusion
Argument against
There appear to be some reasons not to give /Mactams continuously, although most
of these are more of theoretical interest than practical importance. It is conceivable that,
in some situations, intermittent dosing would result in higher concentrations at the site
of infection than would continuous infusion. One would be infection at a site with a
rate-limiting active transport mechanism eliminating the antibiotic from the site. During
continuous infusion, the antibiotic would be eliminated from the site continuously at
a maximum rate, resulting in persisting low concentrations, while during intermittent
infusion a maximum rate of elimination would still result in efficacious concentrations
being maintained for some time. Examples would be infections in eye or cerebrospinal
fluid. However, the kinetics of the enzymes make this scenario appropriate only over
a particular range of antibiotic concentrations and then would apply only for those
/Mactams which are handled by such elimination mechanisms.
Another situation would be if antibiotic elimination from a site was due to
/Mactamases, again with a rate-limiting step. For example, while an antibiotic was
diffusing to the centre of an abscess, /Mactamase-producing bacteria could degrade it,
perhaps resulting in antibiotic concentrations near zero during continuous infusion,
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while, because of the rate-limiting nature of the elimination, efficacious concentrations
might be reached for part of the time during intermittent infusion.
In the study by Oyenji et al. (1994), it was found that cefaclor exhibited a marked
inoculum effect against the four pathogens studied, and that there was concentration
dependent killing at a large inoculum. The other test-drug, ceftibuten, did not show such
an effect. From these observations, it follows that not all /Mactams show the same
pharmacodynamic behaviour. Before deciding whether an individual compound can, or
will, be given as a continuous infusion, its precise pharmacodynamic behaviour should
be known; this also holds true for intermittent infusion.
Lastly, two of the more practical problems which have to be considered, are the
stability of the compound to be administered and the costs of the pump which has to
be used. Several antibiotics are very unstable at room temperature and thus cannot be
given as a continuous infusion. Thus, if an antibiotic is given as continuous infusion,
its stability should be considered. For others, such as penicillin, degradation products
can cause hypersensitivity reactions (Smith, Dewdney & Wheeler, 1971).
At which concentration should we aim?
The important question of which concentration should be obtained during continuous
infusion of /Mactam antibiotics is not yet fully answered. From the results of time-kill
curves, it seems that a maximum effect is reached at 4 x MIC for the target bacterium.
A concentration of 4 x MIC was also needed for efficacy in in-vitro pharmacokinetic
models (Mouton & den Hollander, 1994) and, in a recent study to determine the
efficacious in-vivo concentrations of ceftazidime in an experimental P. aeruginosa rabbit
endocarditis model, Xiong et al. (1994) also found 4 x MIC to be a possible therapeutic
goal. Four times the MIC would, therefore, seem to be the concentration to aim at
during continuous infusion. However, dose-ranging studies have not yet been performed
for continuous dosing regimens in vivo. In the studies of Roosendaal et al. (1985, 1986),
the efficacy of continuous infusion is expressed not only as the EDW, but survival per
group per daily dose is presented as well, which permits calculation of the dose needed
for efficacy. They studied efficacy of ceftazidime in a rat pneumonia model due to
Klebsiella pneumoniae, starting therapy either 5 h (moderate infection) or 34 h (severe
infection) after inoculation of the bacteria in the lung. When the animals had developed
a severe infection, after 34 h, bacteraemia and/or sepsis was present in at least some
animals. Furthermore, concentrations of ceftazidime in serum were determined. The
serum concentration of ceftazidime needed during continuous infusion to obtain 50%
efficacy in normal rats was between one-sixth and one-third the MIC, for the infecting
K. pneumoniae, depending on the seventy of the infection. However, the concentration
needed to obtain 100% efficacy (EDioo) was dependent not only on the severity of
infection but also whether the animals were leucopenic or not. In normal rats, the EDioo
to treat animals with moderate infection was approximately one-third of the MIC for
the K. pneumoniae strain and in severe disease was around six times the MIC, while
in neutropenic animals, continuous concentrations of 2 x MIC were necessary to obtain
100% survival in the moderate infection group. This indicates that it is not only the
MIC for the bacterium that should be considered, but also the severity and location
of the infection that needs treatment. Although the results from these animal studies
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are not directly comparable to infections in humans, the results do indicate that there
is a relation to the MIC during (severe) infection.
If the MIC is taken as the benchmark, it follows that, when treating a patient with
continuous infusion of an antibiotic, knowledge of the MIC for the bacterium is more
important than during intermittent infusion, and of more importance than solely a
laboratory report of susceptibility or resistance. The new semi-automatic devices, such
as the Vitek and Microscan systems, which are being used increasingly in clinical
laboratories, determine a type of 'MIC and their results could possibly be used in
clinical practice in the future for a finer attunement of the dose needed. For
microorganisms with a low MIC, the daily dose can then be lowered substantially
(Craig, 1993).
There are two other important issues to be considered, tissue penetration and protein
binding. Although the concentration of an antimicrobial agent in serum may be known,
this could be different in other body compartments (Barza & Cuchural, 1985). Since
/Mactams, in general, distribute into the extracellular body compartment, it is to be
expected that, if there is no active transport, at steady state, the concentration of the
free fraction of the drug is the same in the various body-compartments. Studies from
blister fluid show that, generally, penetration of /Mactams into such fluid is good, and
shows consistent results (Wise, 1986). However, concentrations at the site of infection
may be lower as was discussed above. Secondly, since only the free fraction of the drug
is active, and indeed in animal models was shown to be of importance in relation to
efficacy (Merrikin, Briant & Rolinson, 1983), this is the concentration which should be
taken into account when calculating dose in relation to serum concentrations.
Extracellular tissue fluid contains less protein (about one-third) than serum, and total
concentrations (but not the free fraction) will thus be lower in that compartment (Wise,
1983). The concentration profile in tissue was shown to be similar to that in serum when
only the free fraction of the drug was taken into account (Kunst & Mattie, 1978; Mattie,
Hoogeterp & Hermans, 1987). In studies in human volunteers, comparing concentration
profiles in serum and blister fluid of ceftazidime (Mouton et al., 1990) and meropenem
(Mouton & Michel, 1991) during continuous infusion, total concentrations in blister
fluid were slightly lower.
Pharmacokinetic considerations
The clinically important practical question which arises, is: what dose needs to be
administered to obtain the target concentration? To answer this question, the
pharmacokinetics of the /Mactam should be known. Ceftazidime is one of the few
/Mactams which has been studied extensively during continuous infusion, both in
volunteers and in different patient groups. The results of these studies are summarised
in the Table. There is a large variation in concentrations reached at steady state in
relation to the dose given, as a result of differences in total body clearance.
The concentrations reached in patients with cystic fibrosis (CF) provide a good
example. It has been shown in numerous studies examining intermittent infusion, that
these patients have an increased total body clearance and a larger volume of distribution
as compared to controls for many drugs, including most /Mactam antibiotics (Spino,
1991). As a result, when administered in standard dosages, serum concentrations are
lower and the half-life shorter in CF patients than in other groups. The reasons for these
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differences in clearance and volume of distribution remain debatable (Hedman et al.,
1988; Spino, 1991).
The pharmacokinetics of ceftazidime during continuous infusion have been
investigated in CF patients (Table). From these studies it has become clear that higher
daily dosages are needed in order to obtain comparable serum concentrations during
continuous infusion in CF patients. Studying the pharmacokinetics of continuous
infusion of penicillin and cloxacillin, Visser et al. (1993) found a large variation in steady
state concentrations, which could be explained largely by differences in renal function.
The findings in these studies indicate that there should, a priori at least, be a reasonable
estimate of both the total clearance and the target concentration of the antibiotic in the
individual patient.
Dose calculations
When it is known what concentrations to aim for, it is relatively easy to calculate which
dose should be given. Pharmacokinetic behavior of /Mactams in serum during
continuous infusion is easy to conceive. When the input per unit of time is known
(continuous infusion) and the output is known (total body clearance) one can calculate
the serum concentrations achieved as: serum concentration = dose/total body
clearance.
Conversely, when the target concentration is known the necessary dose can be
calculated if the total body clearance (TBC) of the drug is known. The elimination rate
constant (Ke), as often reported for intermittent infusion, can be used to calculate the
TBC, which itself is a function of the K* and the volume of distribution (Vd) of the drug:
TBC = Kc x Vi, if there is no important rate-limiting step in the elimination process.
The mean values of TBC, Kc and VA, are known for most drugs (e.g. Mammen, 1990;
Klepser et al., 1995). For drugs which are cleared almost completely by glomerular
filtration, an estimate of the clearance from the creatinine clearance should be
satisfactory. This holds true also for drugs for which the TBC is merely a function of
creatinine clearance, such as meropenem (Mouton & van den Anker, 1995). However,
since these parameters may vary between different patient groups, for instance intensive
care patients, mean values per patient group would be even more informative (Table).
For some drugs with a high tubular excretion rate, such as penicillin and cloxacillin,
however, other factors such as the saturability of tubular elimination may play an
important role in determining the plasma concentrations during continuous infusion.
For these drugs, drug specific nomograms can be of use (Visser el al., 1993).
A more sophisticated method to estimate the TBC, Kc and Kd for a particular patient
would be to use population pharmacokinetic models. In these models, clearance or
elimination rate is related to parameters such as renal function and the volume of
distribution is described as a function of bodyweight or lean body mass. Individual
pharmacokinetic parameters and serum concentrations can be predicted accurately
from population pharmacokinetics. This was recently shown, for instance, for
continuous infusion of ceftazidime in a CF population (Vinks et al., 1995a). Although
there is variation between individuals, the clearances found during continuous infusion
are generally in agreement with those found during intermittent infusion. For drugs
cleared by both renal and extrarenal pathways, for instance meropenem, the same
conclusion can be drawn (Mouton & Michel, 1991). In a similar study in CF patients
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(Vinks et al., \995b), there was no significant difference between the TBC of aztreonam
during both treatment regimens.
From these studies it is clear that, although there is variation between groups of
patients, the concentrations reached during continuous infusion for most drugs do not
differ between patients by more than a factor of two, provided there is no renal
insufficiency. If time above the MIC is taken as the pharmacodynamic parameter for
/?-lactams, it seems to be more important to know the MIC (which is usually determined
to within +1 dilution) for the infecting bacterium than the precise pharmacokinetic
characteristics of the individual patient. The reported MIC for the bacterium and
calculated pharmacokinetic parameters in the patient can then both be used to
determine the dose necessary to obtain the desired concentration.
As indicated above, there is a direct inverse relationship between total body clearance
and dose. Figure shows a nomogram translating total body clearance into dose during
continuous infusion in relation to the MIC. From this nomogram, the daily dose to be
administered can be read as a function from the total body clearance (known or
estimated) and the target concentration. For example, if the target concentration is set
at 4 mg/L in a patient with a total body clearance of 180 mL/min, the total daily dose
should be 1000 mg, i.e. approximately 40 mg/h. In this example, the MIC of the
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bacterium might typically have been 1 mg/L with the antibiotic having a low degree of
protein-binding.
Conclusion
It is concluded that, although there are no clinical trials showing continuous infusion
to be superior over intermittent infusion, there are at least theoretical arguments, results
of animal studies in favour and case reports supporting efficacy of continuous infusion.
From the nomogram presented, it should be easy to calculate daily doses, including in
patients with a decreased clearance. Further clinical trials should be undertaken to show
efficacy in different patient groups and dose-ranging studies are needed to determine the
relationship between MIC and the concentration needed during continuous infusion in
specific circumstances. Although 4 x MIC is a practical goal, this value is dependent
both on the host and the infecting bacterium.
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